Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Potential save search
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.41 5.26% 4.99% 390K
|
Professional, Scientific, and T...
|
| O: 2.17%
H: 5.06%
C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Published: 2024-04-22 (Crawled : 20:00) - globenewswire.com
TOVX | News | $0.3769 -8.3% -1.83% 1.2M
|
Manufacturing
|
| O: 2.44%
H: 0.0%
C: -9.52%
vcn-01 cancer pancreatic cell preclinical for meeting potential therapy
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
| Email alert
Add to watchlist
ENDP | News | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
solution for nationwide potential injection
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.965 4.04% 3.88% 410K
|
Health Technology
|
| O: 5.2%
H: 4.76%
C: 4.4%
bxcl501 for therapeutics potential market
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
Published: 2024-04-19 (Crawled : 15:00) - prnewswire.com
VERV | $6.88 -0.43% -0.44% 960K
|
Professional, Scientific, and T...
|
| O: -2.23%
H: 3.19%
C: 0.76%
for potential
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
sclerosis for potential
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | News | $1.73 -8.95% -9.83% 440K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Published: 2024-04-10 (Crawled : 11:00) - biospace.com/
TBPH | $9.21 -2.64% -2.71% 340K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
TBPH | $9.21 -2.64% -2.71% 340K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 7.89%
H: 1.95%
C: -2.93%
first levosimendan treatment ongoing for therapeutics potential
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
SNOA | $0.1574 4.76% 150K
|
Health Technology
|
| O: -6.39%
H: 10.21%
C: 8.18%
australia publication pharmaceuticals infections potential
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
CYCC | $1.805 3.14% 3.05% 28K
|
Health Technology
|
| O: 4.27%
H: 0.0%
C: -5.45%
precision asco cancer pharmaceuticals meeting potential
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Published: 2024-04-01 (Crawled : 10:00) - globenewswire.com
LQDA S | $12.96 -1.67% -1.7% 1.2M
|
Health Technology
|
| O: 2.99%
H: 0.06%
C: -3.74%
fda approval favorable update potential
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
Published: 2024-03-28 (Crawled : 13:30) - globenewswire.com
FBLG | $11.07 2.41% 2.35% 48K
|
|
| O: -1.87%
H: 0.0%
C: -6.24%
patent lupus treatment application technology potential
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: Glo...
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
copd potential market
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData
Published: 2024-03-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
copd potential market
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
fda hypertension potential
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $11.24 -0.09% -0.09% 600K
|
Health Technology
|
| O: -0.16%
H: 8.11%
C: 3.34%
stk-001 first treatment therapeutics potential
DraftKings and Kindbridge Behavioral Health Expand Program That Provides Treatment Resources for Individuals Experiencing Potential Indications of Problem Gaming
Published: 2024-03-21 (Crawled : 20:00) - globenewswire.com
DKNG | News | $41.2 1.6% 1.58% 7.1M
|
Technology Services
|
| O: -0.5%
H: 1.82%
C: -1.07%
health treatment program gaming potential
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.